The expanded partnership will see Lonza extending the manufacturing of the drug substance for the Covid-19 vaccine by Moderna. It will also include the installation of a new manufacturing line for the production of drug substances at Lonza’s site in Geleen.
The new production line will complement Lonza’s existing drug substance production network for the Moderna vaccine. It will contribute an additional 300 million doses per year at 50ug a dose at full capacity.
The new production line is expected to be operational by the end of 2021.
Shares in Lonza last traded flat at $79.97 at 12.29pm before its trading halt request.
